Palatin Technologies, Inc. (PTN)
NCM · Healthcare · Biotechnology
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Palatin Technologies, Inc.
Palatin Technologies, Inc., a biopharmaceutical company, develops first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system in the United States. It is developing oral small molecule PL7737 MC4R agonist in preclinical studies; long-acting peptide MC4R agonists; and Bremelanotide co-administration with Tirzepatide to treat obesity in Phase 2 trial, as well as Bremelanotide co-formulated with a PDE5i for the treatment of ED in patients not adequately responsive to PDE5i monotherapy. The company also develops PL9643 for dry eye disease and anti-inflammatory ocular indications; and oral PL8177 for the treatment inflammatory bowel diseases. Palatin Technologies, Inc. was incorporated in 1986 and is based in Monmouth Junction, New Jersey.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 8.8M | 116K | 3.9M |
| Gross Profit | 0.00 | |||
| Operating Income | (4.6M) | 4.7M | (7.3M) | (1.6M) |
| Net Income | (2.2M) | 4.7M | (7.3M) | (1.4M) |
| Diluted EPS | N/A | $4.26 | $-2.86 | $-0.37 |
Annual Financials
| Metric | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 1.5M | 4.9M | 4.5M | 0.00 |
| Gross Profit | 1.3M | 4.4M | 4.4M | 0.00 |
| Operating Income | (36.6M) | (33.5M) | (30.3M) | (22.7M) |
| Net Income | (36.2M) | (24.0M) | (29.7M) | (17.3M) |
| Diluted EPS | $-189.50 | $-110.50 | $-101.16 | $-32.15 |